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Abstract
Background: Magnesium dose-dependently potentiates the effect of non-depolarizing neuromuscular blocking
agents. We investigated whether the potentiation of rocuronium-induced blockade by magnesium reduces the
effect of sugammadex in an ex-vivo environment and how this influences the safety margin of reversal.
Methods: Phrenic nerve – hemidiaphragm tissue preparations were isolated from male Wistar rats. The specimens
were suspended in a tissue holder that allowed registering muscle contraction amplitude following electrical
stimulation of the nerve. Concentration-response relationships were elucidated for magnesium, as well as for
rocuronium and sugammadex.
Results: The mean (95% confidence interval [CI]) half effective concentrations (EC50) of rocuronium in the presence
of magnesium 1mM or 1.5 mM were 7.50 μM (6.97–8.07 μM) and 4.25 μM (4.09–4.41 μM), respectively (p < 0.0001).
Increasing magnesium from 1mM to 1.5 mM during reversal of rocuronium-induced block increased the mean
(95% CI) EC50 of sugammadex from 3.67 μM (3.43–3.92 μM) to 5.36 μM (5.18–5.53 μM), whereas mean (95% CI)
effective concentrations for 95% effect (EC95) were not significantly different at 7.22 μM (6.09–8.54 μM) and 7.61 μM
(7.05–8.20 μM), respectively (p = 0.542). When rocuronium-induced block was reversed to a train-of-four (TOF)
ratio > 0.9, but with still visible fade, increasing magnesium from 1mM to 2 mM decreased the TOF ratio to below
0.9. If there was no visible fade after reversal, increasing magnesium concentration did not reduce the TOF ratio.
Conclusions: Magnesium potentiates the neuromuscular effect of rocuronium and shifts the concentration-response
curve to the left. Magnesium decreases the safety margin of reversal of rocuronium-induced neuromuscular block with
sugammadex.
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Background
Magnesium is one of the most abundant cations in the
body and plays a fundamental role as a co-factor in several
enzymatic reactions and physiological processes [1, 2]. Its
medicinal uses include treatment of arrhythmias [1],
bronchospasm [3], pre-eclampsia and eclampsia [1], toco-
lysis [1], cerebral vasospasm [4], and lately as an adjunct
to pain therapy [5].
Magnesium also has several neuromuscular effects,
such as decreased liberation of acetylcholine from the
presynaptic membrane in the neuromuscular junction
[6, 7], a decreased depolarizing effect of acetylcholine on
the motor end plate [7] and reduced excitability of the
muscle fiber [7]. These effects also influence the action
of neuromuscular blocking agents (NMBA): depolarizing
NMBAs are antagonized by magnesium [8], while
non-depolarizing NMBAs are potentiated, resulting in a
faster onset time [9–12] and prolonged clinical effect [9,
12–15]. Several clinical studies found that magnesium
administration prior to the injection of NMBA does not
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significantly impact the efficacy of sugammadex [16, 17],
whereas case studies have reported that if magnesium
was administered after spontaneous recovery [18] or re-
versal with sugammadex [19], the significant return of
neuromuscular block was seen. A recent pre-clinical
study found that while time to recovery was not system-
atically increased by magnesium for reversal of
rocuronium-induced block with equimolar sugammadex,
maximal achieved TOF ratio was lower with higher
magnesium concentrations [20].
In this study, we used rat phrenic nerve – hemidiaph-
ragm preparations as a controlled ex vivo experimental sys-
tem to determine the changes in pharmacodynamics
caused by magnesium in the rocuronium-sugammadex
interaction. The experimental set up allowed us to investi-
gate effects on the neuromuscular junction under
near-physiological conditions with constant ion concentra-
tions, while at the same time eliminating such confounding
factors as systemic redistribution, drug metabolism and ex-
cretion. We hypothesized that unbound rocuronium is po-
tentiated by magnesium, resulting in a reduced effect of
sugammadex for reversal of neuromuscular block. Our re-
sults highlight the negative impact of magnesium on the
safety margin of reversal of neuromuscular block.
Methods
Animals, ethics
A total of 20 male Wistar rats from Toxi-Coop Toxico-
logical Research Center, Dunakeszi, Hungary, ranging in
weight from 250 to 563 g were used. Institutional guide-
lines for animal care and usage for research principles
were strictly followed. All procedures involving animals
were approved by the University of Debrecen Committee
of Animal Research (1/2013/DE MÁB). Animals were
chosen randomly on the morning of the experiment and
euthanized prior to harvesting of tissue specimens.
Materials
Rocuronium (Esmeron; MSD Pharma Hungary, Budapest,
Hungary) and sugammadex (Bridion; MSD Pharma
Hungary, Budapest, Hungary) were purchased from com-
mercial vendors and diluted in Krebs-buffer as needed to
achieve a dosing volume of 10–100 μl.
Magnesium heptahydrate sulfate (Cormagnesin, Wör-
wag Pharma GmbH, Böblingen, Germany) was pur-
chased from the commercial vendor and given undiluted
to the buffer solution to achieve the indicated final con-
centrations for magnesium.
Experimental procedures
The rat phrenic nerve – hemidiaphragm system was
used for our experiments. Originally described by Bülbr-
ing [21], this technique has been a useful tool to investi-
gate neuromuscular blocking and reversal agents [20, 22,
23]. Rats were given an intraperitoneal overdose of so-
dium thiopental (60 mg/kg) and exsanguinated through
the incision of the dorsal vena cava. Hemidiaphragm
preparation was performed by bilateral thoracotomy and
removal of the sternum, after which both phrenic nerves
were dissected from cranial to rostral direction to the
junction with the diaphragm. Then both hemidiaph-
ragms were excised with the corresponding phrenic
nerve intact. The hemidiaphragms were then secured in
a special tissue holder (ISO-07-TSZ2D, Experimetria
Ltd., Hungary) in 75mL of Krebs-puffer (110 mM NaCl,
5 mM KCl, 1.25 mM CaCl2, 1 mM MgSO4, 1 mM
KH2PO4, 5 mM glucose, 20 mM NaHCO3) and aerated
by bubbling 95% O2 + 5% CO2 (Vol%) through the solu-
tion. The solution was maintained at a temperature of
37 °C (AMP-09 Temperature controller, Experimetria
Ltd., Hungary).
The hemidiaphragms were attached to an isometric
force-displacement transducer (FSG-01/200 Force Trans-
ducer, Experimetria Ltd.) at the centrum tendineum using
a commercially available 5/0 diameter surgical thread.
Measurements were amplified by AMP-01-SG Classic
bridge amplifier and recorded with the S.P.E.L. Advanced
Isosys software (Experimetria Ltd., Hungary). The phrenic
nerve was stimulated either with a single twitch every 5 s
(rectangular pulses with 0.3ms pulsewidth and supramax-
imal voltage) or a 2-Hz train-of-four (TOF) stimulus every
15 s (rectangular pulses of 0.2 ms duration with a supra-
maximal voltage) using a square wave stimulator
(ST-03-O4, Experimetria Ltd., Hungary).
After submersion in buffer solution, the tissue prepara-
tions were allowed an acclimatization period of 10min
without stimulation at an applied tension of 20–30 mN.
Then stimulation was started and an additional 1–1.5 h
without treatment (with buffer changes as needed)
followed until a stable baseline tension was achieved. Drug
dosing was only commenced after this stabilization period
(for a scheme of drug dosing and study design, see Fig. 1).
After the measurement of a given concentration-response
curve, the buffer solution was removed 5 times in a
30-min timespan to assure complete washout of any
agents before measuring a new curve.
Each concentration-response relationship shown in
the figures is based on 5 concentration-response curves,
each from a different specimen. Whereas multiple
concentration-response curves were measured on a
given specimen, a specific concentration-response curve
was measured only once, thus each specimen only con-
tributed one data set to a given concentration-response
relationship. To mitigate the effects of degradation of
the tissue specimen over time, the order of
concentration-response curve experiments was per-
muted between specimens. The specimen was discarded
if a stable baseline tension was no longer attainable.
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Concentration-response curves for magnesium and
rocuronium
The effects of magnesium and rocuronium were quanti-
fied as the depression of single twitch force amplitude.
The twitch force amplitude for a measurement point
was the mean value of five consecutive contractions at a
given drug concentration once contraction amplitude
had stabilized corrected with the baseline tension. The
twitch force amplitude was normalized to the maximum
twitch force amplitude of the untreated sample to con-
struct cumulative concentration-response curves.
In the case of magnesium, 9.2 mg was administered
every 10 min to the buffer solution until full depression
of the twitch amplitude. Each specimen contributed 11–
12 measurement points to the curve.
For rocuronium, a dose was given every 15min. We
constructed two curves, one for [Mg2+] = 1mM and the
other for [Mg2+] = 1.5 mM. For the case of [Mg2+] = 1
mM the initial dose of rocuronium was 0.2 mg followed
by doses of 0.1 mg until contraction was no longer de-
tectable after nerve stimulation. Each specimen
contributed 5–7 measurement points to the curve. For
the case of [Mg2+] = 1.5 mM, the first dose was 0.1 mg,
then two doses of 0.05 mg followed by doses of 0.025 mg
until contraction was no longer detectable after nerve
stimulation. Each specimen contributed 7–11 measure-
ment points to the curve.
Pre-block effect of magnesium
To determine the pre-block effect of magnesium on re-
versal of neuromuscular block, a single rocuronium dose
(0.3 mg rocuronium for [Mg2+] = 1.5 mM and 0.5 mg
rocuronium for [Mg2+] = 1 mM) was given to achieve a
90–95% depression of single twitch force amplitude.
Then sugammadex doses were given in 10-min intervals.
Twitch force amplitude was baseline corrected with the
twitch force amplitude of the sample prior to reversal
with sugammadex and normalized to the maximum con-
traction amplitude after full reversal to construct cumu-
lative concentration-response curves. For [Mg2+] = 1 mM
an initial sugammadex dose of 0.2 mg was given,
followed by four doses of 0.1 mg, then 0.15 mg, which
Fig. 1 Study design. a Concentration-response curve for magnesium. Magnesium doses were added every 10min to the buffer solution until the
suppression of single twitch force amplitude was achieved. b Concentration-response curve for rocuronium. Rocuronium boluses were added
every 15min until the suppression of single twitch force amplitude was achieved. To assess the effect of magnesium, the experiment was repeated
with a magnesium bolus given 10min prior to commencing rocuronium dosing. c Concentration-response curve for sugammadex. After an initial
bolus of rocuronium which caused at least 90% suppression of single twitch force amplitude, sugammadex doses were given every 10min until full
recovery of single twitch force amplitude was achieved. To assess the effect of magnesium given before neuromuscular block, the experiment was
repeated with a magnesium bolus given 10min prior to administering the rocuronium dose. To assess the effect of magnesium given after the
establishment of neuromuscular block, the experiment was repeated with a magnesium bolus given after partial reversal with sugammadex and then
sugammadex dosing was continued. d Effect of magnesium on the safety margin of reversal. An initial rocuronium dose was followed by incremental
doses of sugammadex to achieve either a “full” or clinically “accepted” reversal, as measured by the train-of-four (TOF) ratio. Magnesium was given in
increments and the TOF ratio reassessed after every change in magnesium concentration. Mg: magnesium, Roc: rocuronium, Sug: sugammadex, TOF:
measurement of train-of-four ratio
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was followed by doses of 0.25 mg until twitch amplitude
plateaued and reversal of neuromuscular block was veri-
fied by achieving a TOF ratio (T4/T1 of the four stim-
uli) > 0.9. Each specimen contributed 5–8 measurement
points to the curve. For [Mg2+] = 1.5 mM an initial
sugammadex dose of 0.05 mg was given, followed by
three doses of 0.1 mg, then 0.15 mg, which was followed
by doses of 0.25 mg until twitch amplitude plateaued
and reversal of neuromuscular block was verified by
achieving a TOF ratio (T4/T1 of the four stimuli) > 0.9.
Each specimen contributed 7 measurement points to the
curve.
Post-block effect of magnesium
To determine the post-block effect of magnesium, rocur-
onium 0.5 mg was given at [Mg2+] = 1 mM to achieve a
90–95% depression of single twitch force amplitude. Re-
versal was started with incremental doses of 0.1–0.2 mg
sugammadex every 10min until a cumulative dose of
0.5 mg was achieved. At this point [Mg2+] was increased
to 1.5 mM and sugammadex dosing was continued with
one dose of 0.15 mg, followed by one dose of 0.1 mg.
This was followed by doses of 0.25 mg until twitch amp-
litude plateaued and reversal of neuromuscular block
was verified by achieving a TOF ratio > 0.9. Twitch force
amplitude was baseline corrected with the twitch force
amplitude of the sample prior to reversal with sugamma-
dex and normalized to the maximum contraction ampli-
tude after full reversal to construct cumulative
concentration-response curves. Each specimen contrib-
uted 6–7 measurement points to the curve.
Effect of magnesium on the safety margin of reversal
The effect of magnesium on the safety margin of reversal
was investigated by reversing rocuronium-induced neuro-
muscular block with sugammadex until either the TOF ra-
tio was ≈ 1.0 without visible fade (“full” reversal) or TOF
ratio was > 0.9, but still showed a visible fade (“accepted”
reversal [24]). Then [Mg2+] was increased in 0.5mM steps
from 1mM to 2mM. TOF ratio was recorded every 15 s
for 10min after a change in [Mg2+] and the final stable
TOF ratio was used to quantify the change in the TOF
ratio.
Statistical analysis
GraphPad Prism 6 for Windows (GraphPad Software, Inc., La
Jolla, CA, USA) was used for fitting of concentration-response
curves. Curve fitting was done by nonlinear regression with ei-
ther the “log (agonist) vs. normalized response – variable
slope” or the “log (inhibitor) vs. normalized response – vari-
able slope” function. The fitting equation was: y = 100/(1 +
10^((LogEC50-X)*HillSlope)), where X is the log10 value of
concentration and y is the normalized and baseline corrected
contraction amplitude.
For sample size determination, we performed a pilot
study (n = 3) to determine the concentration-response
curve of rocuronium. We arrived at values of logEC50 =
0.875 and SD = 0.023. Assuming a 10% change in EC50
as clinically relevant, group sample size at α = 0.05 and
power of 80% was 4 for a one-sided test. Statistical com-
parison of concentration-response curves was done with
GraphPad Prism 6 for Windows with the extra
sum-of-squares F-test. LogEC50 was the model compo-
nent that was used to account for the extra
sum-of-squares. Results are presented as mean and 95%
confidence interval unless otherwise specified.
Results
The effect of magnesium on the diaphragm contraction
force
As a first step, we determined the concentration-response
curve of magnesium alone (Fig. 2). The effective concen-
tration for 50% effect (EC50) was 4.06mM (95% CI: 3.91–
4.21mM). From the concentration-response curve, we
can see that increasing the concentration of magnesium
from 1mM to 1.5 mM resulted in a mean reduction of
contraction force amplitude to 96.6% (95% CI: 91.4–
101.8%) of the amplitude measured with 1mM magne-
sium concentration.
The effect of magnesium on rocuronium-induced
neuromuscular block
The concentration-response curve of rocuronium was
determined with a magnesium concentration of either 1
or 1.5 mM in the buffer solution (Fig. 3). Increasing the
magnesium concentration resulted in a left-shift of the
concentration-response curve. The EC50 values with a
Fig. 2 The concentration-response curve of magnesium. Normalized
contraction force amplitude as a function of magnesium concentration
on a logarithmic scale (logarithm to base 10/ log10). The curve is the best
fit curve calculated from measurements on n= 5 different specimens by
non-linear regression. Measurement points represent mean values of
normalized contraction force amplitude at a given concentration. Error
bars show the standard deviation of measurement points
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magnesium concentration of 1 or 1.5 mM were 7.50 μM
(6.93–8.12 μM) and 4.26 μM (4.09–4.43 μM), respect-
ively (p < 0.0001). The effective concentrations for 95%
effect (EC95) were 12.89 μM (10.67–15.56 μM) and
7.35 μM (6.64–8.13 μM), respectively (p < 0.0001). Best
fit values of concentration-response curves are summa-
rized in Table 1.
The effect of magnesium on the reversal of rocuronium-
induced neuromuscular block with sugammadex
Neuromuscular block was induced with rocuronium with
a magnesium concentration of either 1 or 1.5mM in the
buffer solution and then reversed with incremental doses
of sugammadex (Fig. 4). Due to potentiation of neuromus-
cular block, rocuronium dose had to be modified with the
higher magnesium concentration to achieve the same level
of block as with the lower magnesium concentration.
Therefore rocuronium dose was reduced from 0.5 mg with
a magnesium concentration of 1mM to 0.3mg for a mag-
nesium concentration of 1.5 mM. The EC50 values of
sugammadex with a magnesium concentration of 1 or 1.5
mM were 3.67 μM (3.43–3.92 μM) and 1.51 μM (1.42–
1.60 μM), respectively. The EC95 values were 7.22 μM
(6.09–8.54 μM) and 4.48 μM (3.80–5.29 μM), respectively.
The differences in EC50 and EC95 were statistically signifi-
cant (p < 0.0001 for EC50 and p = 0.002 for EC95).
To assess the effect of post-block administration of
magnesium, magnesium was increased after partial re-
versal of rocuronium-induced block with sugammadex
(Fig. 5). Increasing magnesium concentration in this set-
ting resulted in a sharp drop in contraction force ampli-
tude and a corresponding increase in EC50 of
sugammadex from 3.67 μM (3.43–3.92 μM) to 5.36 μM
(5.18–5.53 μM), which was a statistically significant dif-
ference (p < 0.0001). However, EC95 values were statisti-
cally non-significantly different (p = 0.542) at 7.22 μM
(6.09–8.54 μM) and 7.61 μM (7.05–8.20 μM).
Effect of magnesium on the safety margin after reversal
of neuromuscular block with sugammadex
Since the addition of magnesium after partial reversal
with sugammadex resulted in a decrease in contraction
force amplitude and an increase in the steepness of the
concentration-response curve, we wanted to investigate
whether traditional measures of safe reversal of neuro-
muscular block are still reliable under the condition of
changing magnesium concentrations. Therefore neuro-
muscular block was reversed to achieve either “full” re-
versal (mean TOF ratio: 0.99 ± 0.006, no visible fade) or
a clinically “accepted” safe reversal (TOF ratio > 0.9;
mean TOF ratio: 0.95 ± 0.02, but with visible fade) and
then magnesium concentration was increased incremen-
tally (Fig. 6). The sugammadex to rocuronium concen-
tration ratio was 1.43 (0.83–2.02) in the “full” reversal
group and 0.68 (0.60–0.76) in the clinically “accepted”
reversal group. Whereas TOF ratio remained stable with
increases in magnesium concentration in the “full” rever-
sal group, we witnessed a gradual decline in TOF ratio
and the return of neuromuscular block to below a TOF
ratio of 0.9 in the clinically “accepted” reversal group.
Discussion
In this ex vivo study, we investigated the neuromuscular
effects of magnesium and its interaction with rocuro-
nium and sugammadex. In agreement with previous
studies, magnesium in itself induced dose-dependent
suppression of muscle contraction force [20, 25]. The
mechanism of magnesium’s neuromuscular effect is
multifactorial, including decreased liberation of acetyl-
choline from the presynaptic membrane in the neuro-
muscular junction [7] and a decreased depolarizing
effect of acetylcholine on the motor end plate [7]. These
effects can be reversed by increasing the calcium con-
centration, implicating antagonism of calcium as an
underlying cause [7].
Magnesium also caused a left-shift in the
concentration-response curve of rocuronium, similar to
its effect on d-turbocurarine [25]. The interaction be-
tween magnesium and rocuronium appears to be syner-
gistic, as the reduction in muscle contraction force
exceeds the sum of isolated rocuronium and magnesium
effect. Previously it was suggested that this might be at-
tributed to decreased liberation of acetylcholine from
presynaptic nerve terminals due to an inhibition a
voltage-gated calcium channels by magnesium [20],
however, there is also in vitro evidence for receptor-level
Fig. 3 The concentration-response curve of rocuronium at magnesium
concentrations of 1 and 1.5mM. Normalized contraction force amplitude
as a function of rocuronium concentration on a logarithmic scale
(logarithm to base 10). The curve is the best fit curve calculated from
measurements on n= 5 different specimens by non-linear regression.
Measurement points represent mean values of normalized contraction
force amplitude at a given concentration. Error bars show the standard
deviation of measurement points
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synergism in the case of vecuronium and magnesium
[26].
Upon first inspection, pre-block administration of mag-
nesium enhanced the actions of sugammadex as well.
However, one has to consider the dose-sparing effect of
magnesium, resulting in lower rocuronium concentrations to achieve the same level of neuromuscular block. There-
fore the amount of NMBA sugammadex has to bind is
less, which might explain the apparent left-shift in the
concentration-response curve of sugammadex. Con-
versely, if we increased the concentration of magnesium
only after commencing reversal of block (at partial recov-
ery), the potentiation of rocuronium-induced neuromus-
cular block by additional magnesium increased the depth
of block and shifted the concentration-response curve of
sugammadex to the right. This effect might be attributed
to the synergism between magnesium and unbound
rocuronium molecules. However, even under these cir-
cumstances, we saw no significant increase in the full re-
versal dose of sugammadex. Although we cannot entirely
rule out an interaction between magnesium and sugam-
madex from our data, previous microcalorimetry experi-
ments failed to show any affinity between magnesium and
sugammadex [27]. Therefore, the likelihood of a clinically
significant interaction between magnesium and sugamma-
dex is small and probably not relevant when compared
with the more pronounced potentiation of rocuronium’s
effect by magnesium.
A previous case report with vecuronium found that
magnesium sulphate administration after spontaneous
recovery to a TOF ratio > 0.7 was able to induce a pro-
found return of neuromuscular block [18]. The same
Table 1 Best fit values of concentration-response curves for
rocuronium and sugammadex
Curve Mean (95% CI)
EC50
Mean (95% CI)
EC95
Magnesium 4.06 (3.91–4.21)
mM
Rocuronium
([Mg2+] = 1 mM)
7.50 (6.93–8.12)
μM
12.89 (10.67–15.56)
μM
Rocuronium
([Mg2+] = 1.5 mM)
4.26 (4.09–4.43)
μM
7.35 (6.64–8.13)
μM
p < 0.0001 p < 0.0001
Sugammadex
(Rocuronium 0.5 mg, [Mg2+] = 1
mM)
3.67 (3.43–3.92)
μM
7.22 (6.09–8.54)
μM
Sugammadex
(Rocuronium 0.3 mg, [Mg2+] =
1.5 mM)
1.51 (1.42–1.60)
μM
4.48 (3.80–5.29)
μM
p < 0.0001 p < 0.002
Sugammadex
(Rocuronium 0.5 mg,
[Mg2+] = 1 + 0.5 mM)
5.36 (5.18–5.53)
μM
7.61 (7.05–8.20)
μM
p < 0.0001 p = 0.542
The displayed p-values are in comparison with the reference concentration-
response curve measured with [Mg2+] = 1 mM. EC50: effective concentration for
50% effect, EC95: effective concentration for 95% effect, CI: confidence interval
Fig. 4 The concentration-response curve of sugammadex for
reversing rocuronium-induced block at pre-block magnesium
concentrations of 1 and 1.5 mM. Normalized contraction force
amplitude as a function of sugammadex concentration on a
logarithmic scale (logarithm to base 10). Due to potentiation of
neuromuscular block by magnesium, dose of rocuronium for
achieving block was either 0.3 mg ([Mg2+] = 1.5 mM) or 0.5 mg
([Mg2+] = 1 mM). The curve is the best fit curve calculated from
measurements on n = 5 different specimens by non-linear
regression. Measurement points represent mean values of
normalized contraction force amplitude at a given concentration.
Error bars show the standard deviation of measurement points
Fig. 5 Effect of post-block administration of magnesium on the
concentration-response curve of sugammadex for reversing rocuronium-
induced block. Normalized contraction force amplitude as a function of
sugammadex concentration on a logarithmic scale (logarithm to base 10).
After an initial dose of 0.5mg rocuronium at [Mg2+] = 1mM, the block was
reversed by sugammadex at either unchanged magnesium concentration
(○) or by increasing [Mg2+] to 1.5mM after partial reversal (■). Magnesium
concentration was only increased after partial reversal (indicated by black
arrow) to be able to visualize contractions despite potentiation of the block
by magnesium. The black dashed line (⁃⁃⁃) shows actual normalized
contraction force amplitude, whereas the grey dotted line (● ● ●) is the
best fit curve calculated from measurements on n=5 different specimens
by non-linear regression. Measurement points represent mean values of
normalized contraction force amplitude at a given concentration. Error bars
show the standard deviation of measurement points
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phenomenon was described for a patient who received a
large dose of magnesium for the treatment of atrial fibrilla-
tion after rocuronium-block was reversed with sugammadex
[19]. Our own results show that even with a reversal to an
accepted safe level [17] (TOF ratio > 0.9) this effect persists
and only complete reversal prevents the magnesium-induced
return of neuromuscular block. The degree of the recurrent
block can be sufficient to revert a previously safely reversed
neuromuscular block to the level of unsafe to extubate (TOF
ratio < 0.9). The change in the concentration of magnesium
necessary for this degree of TOF depression can be achieved
with relatively small doses, as even the highest concentration
in our study was still in the near-physiological range. The
sugammadex to rocuronium concentration ratio shows that
with full reversal there is a surplus of sugammadex mole-
cules, so given the 1:1 binding ratio of sugammadex for
rocuronium [27], all rocuronium molecules are encapsulated.
However, if the neuromuscular block is only reversed to
TOF ratio > 0.9, a significant fraction of rocuronium mole-
cules will not be encapsulated by sugammadex. Our results
indicate 25–40% of rocuronium molecules are not bound in
this scenario, which is in line with results from a mouse sys-
tem [27]. Likely the potentiation of these free rocuronium
molecules results in the decrease in TOF ratio following
magnesium administration.
The ex vivo nature of our study poses limitations with
regards to the direct clinical applicability of the results.
One major confounder is that through a large portion of
the preparation process the tissue specimen is in a hyp-
oxic state. At present we do not know what kind of re-
ceptor level changes this might induce or how this
might affect intracellular ion trafficking and utilization.
However, any such effects should be uniform among
specimens as they were harvested in a similar fashion.
The distinct advantage of this ex vivo system is that it al-
lows the precise quantitative characterization of phe-
nomena to a degree that is hard to achieve in in vivo, let
alone clinical studies. Connections and interactions that
are otherwise masked by the gross dosing of study drugs
(relative to the concentration-response curve) or study
endpoints that are only surrogates of actual efficacy (i.e.
time to reversal of block with a fixed dose of sugamma-
dex as opposed to an actual concentration-response rela-
tionship) can be thus uncovered. If the available clinical
data are interpreted in the context of our ex vivo find-
ings, several clinically relevant assumptions regarding
the effects of magnesium can be made.
When magnesium is given prior to initiation of neuro-
muscular block and there is no compensatory reduction
in non-depolarizing NMBA dose, then potentiation and
left-shift of the concentration-response curve will cause
a faster onset time and a prolonged block, as has already
been shown for vecuronium and rocuronium [9, 11, 12].
While one could expect potentiation of neuromuscular
block by magnesium pretreatment to prolong reversal
with sugammadex, two clinical studies failed to show
any significant effect [16, 17]. An ex vivo study also
came to the conclusion that increasing magnesium con-
centration does not systematically increase reversal time
by sugammadex [20].
When magnesium is administered after the non-
depolarizing NMBA or during a/following reversal, then total
reversal dose of sugammadex is still unchanged, however,
the degree of neuromuscular block caused by unbound
NMBAs will be increased [28]. Magnesium given after in-
complete spontaneous recovery or pharmacological reversal
can cause a recurrent neuromuscular block, even if the TOF
ratio is > 0.9 [19, 29]. The degree of the block can be clinic-
ally significant even if the concentration of magnesium re-
mains in the near-physiological range. Therefore magnesium
should be administered carefully postoperatively and quanti-
tative neuromuscular monitoring is advised to confirm full
reversal and exclude return of neuromuscular block, even
when using sugammadex.
Conclusion
In our ex vivo system magnesium exhibited a marked en-
hancement of the neuromuscular block caused by rocuro-
nium and shifted the concentration-response curve of
rocuronium to the left. Although the interaction of sugam-
madex and rocuronium was not significantly influenced by
magnesium, the potentiation of unbound rocuronium by
magnesium caused a decrease in the safety margin of rever-
sal and was only prevented by a full reversal of neuromuscu-
lar block by sugammadex.
Fig. 6 Magnesium-induced change in the train-of-four (TOF) ratio.
Train-of-four ratio as a function of magnesium concentration. After
an initial dose of rocuronium 0.5 mg, sugammadex was given in
incremental doses to either achieve a clinically “accepted” (1 >
TOF > 0.9, but with still visible fade) or “full” reversal (TOF ≈ 1.0, no
visible fade). Magnesium concentration was then increased to 1.5
mM and then again to 2 mM. For each reversal type n = 5 different
specimens were measured. Measurement points represent mean
values of TOF ratio at a given concentration. Error bars show the
standard deviation of measurement points
Fábián et al. BMC Anesthesiology           (2019) 19:64 Page 7 of 8
Abbreviations
NMBA: Neuromuscular blocking agents; TOF: Train of four
Acknowledgments
none
Funding
the work was supported by the Hungarian Brain Research Program [grant
number 2017-1.2.1-NKP-2017-00002], the founder is the Hungarian Academy
of Sciences, including cost of animals, consumables and publication costs.
Availability of data and materials
data will be available upon request from the corresponding author.
Authors’ contributions
ÁF, VCs, MF: performing animal experiments, statistical analysis, drafting the
manuscript, BF, ET: concept of the study, drafting the manuscript. All authors
have read and approved the manuscript.
Ethics approval
All procedures involving animals were approved by the University of
Debrecen Committee of Animal Research (1/2013/DE MÁB).
Consent for publication
all authors read and approved the manuscript.
Competing interests
Béla Fülesdi is member of the editorial board of BMC Anesthesiology, the
other authors do not have competing interests to report.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 31 August 2018 Accepted: 16 April 2019
References
1. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology.
Br J Anaesth. 1999;83:302–20.
2. Schwalfenberg GK, Genuis SJ. The Importance of Magnesium in Clinical
Healthcare. Scientifica (Cairo). 2017;2017:4179326. https://doi.org/10.1155/
2017/4179326.
3. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in
acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000;36:191–7.
4. Stippler M, Crago E, Levy EI, Kerr ME, Yonas H, Horowitz MB, Kassam A.
Magnesium infusion for vasospasm prophylaxis after subarachnoid
hemorrhage. J Neurosurg. 2006;105:723–9.
5. De Oliveira GS, Castro-Alves LJ, Khan JH, McCarthy RJ. Perioperative systemic
magnesium to minimize postoperative pain: a meta-analysis of randomized
controlled trials. Anesthesiology. 2013;119:178–90.
6. Hubbard JI, Jones SF, Landau EM. On the mechanism by which calcium and
magnesium affect the release of transmitter by nerve impulses. J Physiol.
1968;196:75–86.
7. del Castillo J, Engbaek L. The nature of the neuromuscular block produced
by magnesium. J Physiol. 1954;124:370–84.
8. Tsai SK, Huang SW, Lee TY. Neuromuscular interactions between
suxamethonium and magnesium sulphate in the cat. Br J Anaesth. 1994;72:
674–8.
9. Fuchs-Buder T, Wilder-Smith OHG, Borgeat A, Tassonyi E. Interaction of
magnesium sulphate with vecuronium-induced neuromuscular block. Br J
Anaesth. 1995;74:405–9.
10. James MFM, Schenk PA, Van Der Veen BW. Priming of pancuronium with
magnesium. Br J Anaesth. 1991;66:247–9.
11. Kim M-H, Oh A-Y, Han S-H, Kim J-H, Hwang J-W, Jeon Y-T. The effect of
magnesium sulphate on intubating condition for rapid-sequence
intubation: a randomized controlled trial. J Clin Anesth. 2015;27:595–601.
12. Singh S, Malviya D, Rai S, Yadav B, Kumar S, Sharma A. Pre-treatment with
magnesium sulphate before non depolarizing muscle relaxants: effect on
speed on onset, induction and recovery. Int J Med Sci Public Health. 2014;3:
1238.
13. Kussman B, Shorten G, Uppington J, Comunale ME. Administration of
magnesium sulphate before rocuronium: effects on speed of onset and
duration of neuromuscular block. Br J Anaesth. 1997;79:122–4.
14. Pinard AM, Donati F, Martineau R, Denault AY, Taillefer J, Carrier M.
Magnesium potentiates neuromuscular blockade with cisatracurium during
cardiac surgery. Can J Anesth. 2003;50:172–8.
15. Sinatra RS, Philip BK, Naulty JS, Ostheimer GW. Prolonged neuromuscular
blockade with vecuronium in a patient treated with magnesium sulfate.
Anesth Analg. 1985;64:1220–2.
16. Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of
magnesium sulphate on sugammadex reversal time for neuromuscular
blockade: a randomised controlled study. Anaesthesia. 2015;70:956–61.
17. Czarnetzki C, Tassonyi E, Lysakowski C, Elia N, Tramèr MR. Efficacy of
sugammadex for the reversal of moderate and deep rocuronium-induced
neuromuscular block in patients pretreated with intravenous magnesium: a
randomized controlled trial. Anesthesiology. 2014;121:59–67.
18. Fuchs-Buder T, Tassonyi E. Magnesium sulphate enhances residual
neuromuscular block induced by vecuronium. Br J Anaesth. 1996;76:565–6.
19. Unterbuchner C, Ziegleder R, Graf B, Metterlein T. Magnesium-induced
recurarisation after reversal of rocuronium-induced neuromuscular block
with sugammadex. Acta Anaesthesiol Scand. 2015;59:536–40.
20. Sung T-Y, You H-J, Cho C-K, Choi H, Kim Y, Shin Y, Yang H. Effects of
magnesium chloride on rocuronium-induced neuromuscular blockade and
sugammadex reversal in an isolated rat phrenic nerve–hemidiaphragm
preparation. Eur J Anaesthesiol. 2018;35:193–9.
21. Bülbring E. Observations on the isolated phrenic nerve diaphragm
preparation of the rat. Br J Pharmacol Chemother. 1946;1:38–61.
22. Rhee WJ, Lee SY, Lee JH, Choi SR, Lee S-C, Lee JH, Lee S-I. The effect of high
concentration of magnesium with ropivacaine, gentamicin, rocuronium, and
their combination on neuromuscular blockade. Korean J Anesthesiol. 2015;
68:50–61.
23. Haerter F, Simons JCP, Foerster U, Moreno Duarte I, Diaz-Gil D, Ganapati S,
Eikermann-Haerter K, Ayata C, Zhang B, Blobner M, Isaacs L, Eikermann M.
Comparative effectiveness of Calabadion and Sugammadex to reverse non-
depolarizing neuromuscular-blocking agents. Anesthesiology. 2015;123:
1337–49.
24. Naguib M, Brull SJ, Kopman AF, Hunter JM, Fülesdi B, Arkes HR, Elstein A,
Todd MM, Johnson KB. Consensus statement on perioperative use of
neuromuscular monitoring. Anesth Analg. 2018;127:71–80.
25. Ghoneim MM, Long JP. The interaction between magnesium and other
neuromuscular blocking agents. Anesthesiology. 1970;32:23–7.
26. Wang H, Liang Q, Cheng L, Li X, Fu W, Dai W, Li S. Magnesium sulfate
enhances non-depolarizing muscle relaxant vecuronium action at adult
muscle-type nicotinic acetylcholine receptor in vitro. Acta Pharmacol Sin.
2011;32:1454–9.
27. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of
sugammadex. J Crit Care. 2009;24:29–35.
28. Carron M. Sugammadex after magnesium sulphate administration in a
morbidly obese patient undergoing general anaesthesia. Br J Anaesth. 2014;
112:949–50.
29. Fawcett WJ, Stone JP. Recurarization in the recovery room following the use
of magnesium sulphate. Br J Anaesth. 2003;91:435–8.
Fábián et al. BMC Anesthesiology           (2019) 19:64 Page 8 of 8
